Bristol Accounts Payable vs Current Deferred Revenue Analysis

BMY Stock

USD 58.87 0.64 1.10%

Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Accounts Payable and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Accounts Payable vs Current Deferred Revenue

Accounts Payable vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Accounts Payable account and Current Deferred Revenue. At this time, the significance of the direction appears to have no relationship.

The correlation between Bristol Myers' Accounts Payable and Current Deferred Revenue is 0.09. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Accounts Payable and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Bristol Myers Squibb are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Accounts Payable i.e., Bristol Myers' Accounts Payable and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.09

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Bristol Myers obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bristol Myers Squibb are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At this time, Bristol Myers' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.19 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	36.4B	36.0B	34.3B	36.0B
Total Revenue	46.4B	46.2B	45.0B	47.3B

Gross Profit Total Revenue

Bristol Myers fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity
Total Assets		0.98	0.84	0.93	0.89	0.78	0.98	-0.07	0.9	0.99	0.52	0.83	0.76	0.97	0.45	0.99	0.82	0.02	0.88	0.99	0.7	0.94	0.85	0.96	0.6	0.88
Short Long Term Debt Total	0.98		0.83	0.92	0.84	0.79	1.0	-0.16	0.94	0.97	0.38	0.88	0.82	0.98	0.52	0.99	0.76	-0.04	0.89	0.99	0.76	0.95	0.89	0.94	0.57	0.91
Other Current Liab	0.84	0.83		0.97	0.56	0.71	0.85	-0.17	0.72	0.8	0.57	0.65	0.83	0.85	0.45	0.81	0.49	0.16	0.65	0.87	0.82	0.91	0.72	0.68	0.61	0.78
Total Current Liabilities	0.93	0.92	0.97		0.7	0.8	0.93	-0.07	0.81	0.89	0.52	0.75	0.88	0.95	0.41	0.9	0.66	0.07	0.73	0.94	0.87	0.97	0.84	0.79	0.66	0.85
Total Stockholder Equity	0.89	0.84	0.56	0.7		0.75	0.84	0.13	0.79	0.91	0.41	0.73	0.5	0.82	0.44	0.88	0.9	0.02	0.82	0.85	0.43	0.76	0.73	0.93	0.62	0.81
Property Plant And Equipment Net	0.78	0.79	0.71	0.8	0.75		0.79	0.28	0.73	0.76	0.19	0.7	0.77	0.84	0.41	0.78	0.64	-0.01	0.53	0.8	0.75	0.79	0.78	0.7	0.85	0.85
Net Debt	0.98	1.0	0.85	0.93	0.84	0.79		-0.17	0.9	0.98	0.42	0.83	0.82	0.98	0.52	0.99	0.77	-0.02	0.89	0.99	0.76	0.93	0.89	0.94	0.56	0.91
Retained Earnings	-0.07	-0.16	-0.17	-0.07	0.13	0.28	-0.17		-0.12	-0.07	-0.11	-0.07	-0.11	-0.03	-0.62	-0.12	0.17	0.23	-0.45	-0.11	-0.06	-0.05	-0.16	-0.13	0.44	-0.14
Cash	0.9	0.94	0.72	0.81	0.79	0.73	0.9	-0.12		0.87	0.21	0.98	0.78	0.9	0.48	0.92	0.66	-0.11	0.83	0.91	0.69	0.91	0.85	0.87	0.57	0.84
Non Current Assets Total	0.99	0.97	0.8	0.89	0.91	0.76	0.98	-0.07	0.87		0.53	0.8	0.71	0.95	0.46	0.99	0.84	0.0	0.89	0.98	0.65	0.91	0.83	0.98	0.57	0.86
Non Currrent Assets Other	0.52	0.38	0.57	0.52	0.41	0.19	0.42	-0.11	0.21	0.53		0.12	0.16	0.38	0.18	0.45	0.48	0.15	0.44	0.48	0.18	0.45	0.18	0.44	0.21	0.35
Cash And Short Term Investments	0.83	0.88	0.65	0.75	0.73	0.7	0.83	-0.07	0.98	0.8	0.12		0.76	0.84	0.41	0.85	0.6	-0.17	0.74	0.84	0.67	0.87	0.8	0.8	0.58	0.78
Net Receivables	0.76	0.82	0.83	0.88	0.5	0.77	0.82	-0.11	0.78	0.71	0.16	0.76		0.88	0.35	0.76	0.48	-0.24	0.58	0.8	0.97	0.86	0.87	0.62	0.53	0.8
Good Will	0.97	0.98	0.85	0.95	0.82	0.84	0.98	-0.03	0.9	0.95	0.38	0.84	0.88		0.4	0.97	0.78	-0.04	0.81	0.98	0.83	0.95	0.9	0.9	0.63	0.89
Common Stock Shares Outstanding	0.45	0.52	0.45	0.41	0.44	0.41	0.52	-0.62	0.48	0.46	0.18	0.41	0.35	0.4		0.5	0.2	-0.12	0.69	0.48	0.29	0.4	0.52	0.5	0.27	0.64
Non Current Liabilities Total	0.99	0.99	0.81	0.9	0.88	0.78	0.99	-0.12	0.92	0.99	0.45	0.85	0.76	0.97	0.5		0.8	-0.01	0.9	0.99	0.69	0.93	0.86	0.97	0.58	0.88
Inventory	0.82	0.76	0.49	0.66	0.9	0.64	0.77	0.17	0.66	0.84	0.48	0.6	0.48	0.78	0.2	0.8		-0.02	0.72	0.78	0.45	0.69	0.65	0.85	0.52	0.75
Other Current Assets	0.02	-0.04	0.16	0.07	0.02	-0.01	-0.02	0.23	-0.11	0.0	0.15	-0.17	-0.24	-0.04	-0.12	-0.01	-0.02		-0.12	0.01	-0.19	0.07	-0.25	-0.03	0.23	-0.12
Other Stockholder Equity	0.88	0.89	0.65	0.73	0.82	0.53	0.89	-0.45	0.83	0.89	0.44	0.74	0.58	0.81	0.69	0.9	0.72	-0.12		0.87	0.49	0.77	0.78	0.94	0.3	0.81
Total Liab	0.99	0.99	0.87	0.94	0.85	0.8	0.99	-0.11	0.91	0.98	0.48	0.84	0.8	0.98	0.48	0.99	0.78	0.01	0.87		0.75	0.96	0.87	0.94	0.61	0.89
Property Plant And Equipment Gross	0.7	0.76	0.82	0.87	0.43	0.75	0.76	-0.06	0.69	0.65	0.18	0.67	0.97	0.83	0.29	0.69	0.45	-0.19	0.49	0.75		0.82	0.83	0.54	0.56	0.75
Total Current Assets	0.94	0.95	0.91	0.97	0.76	0.79	0.93	-0.05	0.91	0.91	0.45	0.87	0.86	0.95	0.4	0.93	0.69	0.07	0.77	0.96	0.82		0.85	0.84	0.68	0.86
Short Term Debt	0.85	0.89	0.72	0.84	0.73	0.78	0.89	-0.16	0.85	0.83	0.18	0.8	0.87	0.9	0.52	0.86	0.65	-0.25	0.78	0.87	0.83	0.85		0.82	0.53	0.84
Intangible Assets	0.96	0.94	0.68	0.79	0.93	0.7	0.94	-0.13	0.87	0.98	0.44	0.8	0.62	0.9	0.5	0.97	0.85	-0.03	0.94	0.94	0.54	0.84	0.82		0.5	0.83
Accounts Payable	0.6	0.57	0.61	0.66	0.62	0.85	0.56	0.44	0.57	0.57	0.21	0.58	0.53	0.63	0.27	0.58	0.52	0.23	0.3	0.61	0.56	0.68	0.53	0.5		0.64
Common Stock Total Equity	0.88	0.91	0.78	0.85	0.81	0.85	0.91	-0.14	0.84	0.86	0.35	0.78	0.8	0.89	0.64	0.88	0.75	-0.12	0.81	0.89	0.75	0.86	0.84	0.83	0.64

Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Short Long Term Debt Total	47.5B	51.7B	45.6B	40.7B	41.5B	43.5B
Other Current Liab	7.9B	13.2B	13.0B	13.5B	14.4B	15.1B
Total Current Liabilities	18.3B	19.1B	21.9B	21.9B	22.3B	23.4B
Total Stockholder Equity	51.6B	37.8B	35.9B	31.1B	29.4B	15.0B
Property Plant And Equipment Net	6.3B	6.7B	7.0B	7.5B	8.0B	5.2B
Net Debt	35.2B	37.1B	31.6B	31.6B	30B	31.5B
Retained Earnings	34.5B	21.3B	23.8B	25.5B	28.8B	22.0B
Cash	12.3B	14.5B	14.0B	9.1B	11.5B	12.0B
Non Current Assets Total	100.6B	88.3B	76.1B	69.5B	63.4B	66.6B
Non Currrent Assets Other	6.6B	2.1B	1.7B	1.0B	1.8B	1.9B
Cash And Short Term Investments	12.3B	14.5B	14.0B	9.1B	12.3B	12.9B
Net Receivables	7.7B	8.5B	12.5B	13.9B	15.3B	16.0B
Good Will	22.5B	20.5B	20.5B	21.1B	21.2B	22.2B
Common Stock Shares Outstanding	1.7B	2.3B	2.2B	2.1B	2.1B	1.6B
Liabilities And Stockholders Equity	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Non Current Liabilities Total	59.9B	61.5B	51.4B	43.8B	43.4B	45.6B
Inventory	4.3B	2.1B	2.1B	2.3B	2.7B	1.9B
Other Current Assets	2.0B	5.6B	1.3B	1.7B	1.6B	2.0B
Other Stockholder Equity	18.4B	18.1B	13.1B	6.5B	1.9B	2.0B
Total Liab	78.2B	80.6B	73.3B	65.7B	65.7B	69.0B
Property Plant And Equipment Gross	6.3B	5.9B	11.0B	11.6B	12.8B	13.5B
Total Current Assets	29.4B	30.2B	33.3B	27.3B	31.8B	33.4B
Accumulated Other Comprehensive Income	(1.5B)	(1.8B)	(1.3B)	(1.3B)	(1.5B)	(1.6B)
Short Term Debt	3.5B	2.5B	5.1B	4.4B	3.3B	3.4B
Intangible Assets	64.0B	53.2B	42.8B	36.4B	27.1B	28.4B
Accounts Payable	2.4B	2.7B	2.9B	3.0B	3.3B	1.9B
Short Term Investments	3.0B	1.3B	3.2B	130M	816M	775.2M
Other Liab	15.9B	12.3B	11.0B	7.4B	8.5B	4.9B
Other Assets	4.8B	7.3B	3.3B	2.9B	3.3B	3.3B
Long Term Debt	43.4B	48.3B	39.6B	35.1B	36.7B	38.5B
Treasury Stock	(25.4B)	(26.2B)	(31.3B)	(38.6B)	(43.8B)	(41.6B)
Property Plant Equipment	6.3B	5.9B	6.0B	6.3B	7.2B	5.8B
Current Deferred Revenue	4.5B	3.6B	3.7B	1.3B	8.4B	8.8B
Net Tangible Assets	(34.9B)	(36.0B)	(28.2B)	(25.9B)	(23.4B)	(22.2B)
Noncontrolling Interest In Consolidated Entity	96M	100M	60M	57M	55M	74.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Accounts Payable vs Current Deferred Revenue Analysis

Accounts Payable vs Current Deferred Revenue

Accounts Payable vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Accounts Payable

Current Deferred Revenue

Bristol Myers fundamental ratios Correlations

Bristol Myers Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bristol Myers fundamental ratios Accounts

Also Currently Popular

Additional Tools for Bristol Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.62	Retained Earnings
Other Stockholder Equity	- 0.45	Retained Earnings
Short Term Debt	- 0.25	Other Current Assets
Other Current Assets	- 0.24	Net Receivables
Property Plant And Equipment Gross	- 0.19	Other Current Assets
Other Current Assets	- 0.17	Cash And Short Term Investments